title: Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring.
abstract: Prostatic carcinoma and its treatment have been associated with adverse effects on health-related quality of life (HRQoL). Individual differences in appraisal and coping have been suggested to mediate these HRQoL outcomes. A randomized trial of 65 men with non-localized prostate cancer compared several treatments and tested associations between appraisal, coping, and HRQoL. These patients, and 16 community volunteers matched for age and general health, undertook psychosocial assessments before treatment and after 6 months of treatment. Compared with baseline assessments, men on hormonal treatments reported impaired sexual function. Groups did not differ on emotional distress, existential satisfaction, subjective cognitive function, physical symptoms, or social and role functioning. For individuals, hormonal treatments were more frequently associated with decreased sexual, social and role functioning, but were also associated with improved physical symptoms. In hierarchical regression analysis, HRQoL was lower for men who had more comorbid illnesses, a history of neurological dysfunction, higher threat appraisals, or higher use of coping strategies at baseline. These results showed that pharmacological hormonal ablation for prostate cancer can improve or decrease HRQoL in different domains. HRQoL in men with prostate cancer was associated more strongly with appraisal and coping than with medical variables.
authors.affiliation: School of Psychology, The University of Queensland, Brisbane, Qld, Australia. heather@psy.uq.edu.au
authors.forename: Heather J
authors.initials: HJ
authors.lastname: Green
authors.forename: Kenneth I
authors.initials: KI
authors.lastname: Pakenham
authors.forename: Betty C
authors.initials: BC
authors.lastname: Headley
authors.forename: Robert A
authors.initials: RA
authors.lastname: Gardiner
mesh_terms: D000223:Adaptation, Psychological; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D017373:Cyproterone Acetate / Q000008:administration & dosage / Q000009:adverse effects; D007172:Erectile Dysfunction / Q000139:chemically induced / Q000523:psychology; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017273:Goserelin / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000523:psychology*; D011788:Quality of Life / Q000523:psychology*; D012803:Sick Role
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D017373:Cyproterone Acetate; D016729:Leuprolide